Monocal Disease Interactions
There are 6 disease interactions with Monocal (calcium carbonate / fluoride).
- Phosphate calcifications
- Cardiac contraction/conduction
- Malabsorption
- Renal dysfunction
- Sarcoidosis
- Gastrointestinal bleeding
Calcium salts (applies to Monocal) calcium- phosphate calcifications
Major Potential Hazard, High plausibility. Applicable conditions: Phosphate Imbalance
Elevated serum concentrations of calcium and phosphate can exceed the solubility level and result in calcium- phosphate precipitates that deposit in vascular and renal systems as well as other soft tissues of the body. Therapy with calcium should be administered with extreme caution in patients with hyperphosphatemia (hypoparathyroidism or severe renal impairment). Administration of oral calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. These complexes are eliminated in the feces. Clinical monitoring of serum calcium and phosphate concentrations is necessary.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to Monocal) cardiac contraction/conduction
Major Potential Hazard, High plausibility. Applicable conditions: Arrhythmias
Calcium is involved in cardiac muscle contraction and electrical impulse conduction. Therapy with calcium salt formulations (particularly IV) should be administered cautiously to patients with cardiac disease. Patients receiving cardiac glycosides and concomitant IV calcium may experience arrhythmias. Therapy with IV calcium should be administered slowly and at reduced dosages in patients with cardiac disease.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to Monocal) malabsorption
Major Potential Hazard, High plausibility. Applicable conditions: Achlorhydria, Malabsorption Syndrome
Calcium is absorbed from the intestinal tract by active transport and passive diffusion. Malabsorption syndromes (celiac disease, GI resection), deficiency of vitamin D, parathyroid hormone, or calcitonin, or an alkaline gastric pH (achlorhydria, carbonate or phosphate salts) can decrease the absorption of oral formulations of calcium. Calcium is available in oral and parenteral formulations.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to Monocal) renal dysfunction
Major Potential Hazard, High plausibility.
Absorption of oral calcium formulations may be altered and elimination of calcium by the kidney decreased with renal impairment. Hyperphosphatemia occurs during renal failure. Calcium acetate or calcium carbonate, in addition to providing calcium, complexes phosphates within the GI tract. Calcium carbonate can partially correct metabolic acidosis associated with chronic renal failure. Clinical monitoring of renal function and serum calcium and phosphate concentrations is necessary.
References (2)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
Calcium salts (applies to Monocal) sarcoidosis
Major Potential Hazard, High plausibility.
Hypercalciuria, with or without hypercalcemia, may occasionally occur in patients with sarcoidosis. Elevated calcium levels may result from increased intestinal absorption of calcium, which is related to the extrarenal production of vitamin D by mononuclear phagocytes present within the sarcoid granuloma. Therapy with calcium salts should be administered cautiously and only if necessary in patients with sarcoidosis.
References (3)
- "Product Information. Posture (calcium phosphate, tribasic)." Whitehall-Robbins
- (2001) "Product Information. Neo-Calglucon (calcium glubionate)." Sandoz Pharmaceuticals Corporation
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD (1998) "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division
Fluoride (applies to Monocal) gastrointestinal bleeding
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Colitis/Enteritis (Noninfectious), Gastrointestinal Hemorrhage, Peptic Ulcer
Gastrointestinal toxicity, including GI bleeding has occurred in patients receiving 40 to 65 mg of fluoride daily. Therapy with large dosages of fluoride should be administered cautiously in patients with or predisposed to GI bleeding.
References (1)
- (2001) "Product Information. Fluoritab (fluoride)." Abbott Pharmaceutical
Switch to consumer interaction data
Monocal drug interactions
There are 223 drug interactions with Monocal (calcium carbonate / fluoride).
Monocal alcohol/food interactions
There is 1 alcohol/food interaction with Monocal (calcium carbonate / fluoride).
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
BD PosiFlush SF with BPC
BD PosiFlush SF with BPC is used for medical procedures
Cal-Gest
Cal-Gest is used for duodenal ulcer, erosive esophagitis, GERD, hypocalcemia, indigestion ...
Calcium Oyster Shell
Calcium Oyster Shell is used for duodenal ulcer, erosive esophagitis, GERD, hypocalcemia ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.